Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial

(2014) Takashi Sasaki et al.   ADVANCES IN THERAPY

Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial

(2014) Takashi Kadowaki et al.   ADVANCES IN THERAPY

Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes

(2014) Luca De Nicola et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy

(2014) Hala Yamout et al.   AMERICAN JOURNAL OF NEPHROLOGY

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

(2014) Yukihiro Chino et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

(2014) Kohei Kaku et al.   Cardiovascular Diabetology

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

(2014) Bernard Zinman et al.   Cardiovascular Diabetology

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin

(2014) Takeshi Kadokura et al.   CLINICAL PHARMACOKINETICS

Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study

(2014) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study

(2014) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

(2014) Paul Nyirjesy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study

(2014) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal

(2014) A.J. Scheen et al.   DIABETES & METABOLISM

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

(2014) Fabrice Bonnet et al.   DIABETES & METABOLISM

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

(2014) A.J. Scheen et al.   DIABETES & METABOLISM

Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

(2014) Robert R. Henry et al.   DIABETES CARE

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

(2014) Bruce A. Perkins et al.   DIABETES CARE

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

(2014) Julio Rosenstock et al.   DIABETES CARE

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

(2014) M. A. Nauck et al.   DIABETES OBESITY & METABOLISM

Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study

(2014) A. Kashiwagi et al.   DIABETES OBESITY & METABOLISM

Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin

(2014) S. Grandy et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis

(2014) A. Liakos et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

(2014) T. Forst et al.   DIABETES OBESITY & METABOLISM

Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes

(2014) A. P. Sykes et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

(2014) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise

(2014) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

(2014) S. Sha et al.   DIABETES OBESITY & METABOLISM

SGLT2 inhibitors in the treatment of type 2 diabetes

(2014) Farhad M. Hasan et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

(2014) David Polidori et al.   DIABETOLOGIA

Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

(2014) Greg L. Plosker   DRUGS

Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

(2014) Lesley J. Scott   DRUGS

Tofogliflozin: First Global Approval

(2014) Raewyn M. Poole et al.   DRUGS

Luseogliflozin: First Global Approval

(2014) Anthony Markham et al.   DRUGS

Ipragliflozin: First Global Approval

(2014) Raewyn M. Poole et al.   DRUGS

Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis

(2014) Xu-Ping Yang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

(2014) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

(2014) Elizabeth M Lamos et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

(2014) Nobuya Inagaki et al.   EXPERT OPINION ON PHARMACOTHERAPY

Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition

(2014) William T. Cefalu   JOURNAL OF CLINICAL INVESTIGATION

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with a 28-Week Extension

(2014) Lawrence A. Leiter et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors

(2014) Raymond V. Oliva et al.   Journal of the American Society of Hypertension

The Impact of Weight Loss on Weight-related Quality of Life and Health Satisfaction: Results From a Trial Comparing Canagliflozin With Sitagliptin in Triple Therapy Among People With Type 2 Diabetes

(2014) Shana Traina et al.   POSTGRADUATE MEDICINE

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

(2014) Alan Sinclair et al.   BMC Endocrine Disorders

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

(2014) Michael Nauck   Drug Design Development and Therapy

The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials

(2014) Yu-nan Sun et al.   BMJ Open

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

(2014) André J Scheen et al.   Lancet Diabetes & Endocrinology

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

(2014) Martin Ridderstråle et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

(2014) Anthony H Barnett et al.   Lancet Diabetes & Endocrinology

Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial

(2014) Krzysztof Strojek et al.   Diabetes Therapy

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin

(2013) John P.H. Wilding   ANNALS OF INTERNAL MEDICINE

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

(2013) Clifford J Bailey et al.   BMC Medicine

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

(2013) Martin Ridderstråle et al.   Cardiovascular Diabetology

Sodium Glucose Transport 2 (SGLT2) Inhibition Decreases Glomerular Hyperfiltration

(2013) Robert C. Stanton   CIRCULATION

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

(2013) Stephan A. Veltkamp et al.   CLINICAL DRUG INVESTIGATION

The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor

(2013) Wenhui Zhang et al.   CLINICAL DRUG INVESTIGATION

Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2

(2013) Sreeneeranj Kasichayanula et al.   CLINICAL PHARMACOKINETICS

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers

(2013) Christian Friedrich et al.   CLINICAL THERAPEUTICS

Novel Metabolic Drugs and Blood Pressure: Implications for the Treatment of Obese Hypertensive Patients?

(2013) Stefan Engeli et al.   CURRENT HYPERTENSION REPORTS

Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES CARE

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES CARE

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

(2013) Serge A. Jabbour et al.   DIABETES CARE

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

(2013) D. Polidori et al.   DIABETES CARE

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

(2013) Guntram Schernthaner et al.   DIABETES CARE

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

(2013) S. Macha et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment

(2013) S. Macha et al.   DIABETES OBESITY & METABOLISM

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis

(2013) S. Goring et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

(2013) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

(2013) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2013) J. Bolinder et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

(2013) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

(2013) Mei Zhang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

(2013) F. J. Lavalle-González et al.   DIABETOLOGIA

Canagliflozin: First Global Approval

(2013) Shelley Elkinson et al.   DRUGS

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

(2013) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Canagliflozin, an inhibitor of sodium–glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

(2013) Elizabeth M Lamos et al.   Expert Opinion on Drug Metabolism & Toxicology

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

(2013) J. P. H. Wilding et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)

(2013) Jan N. Basile   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Urinary tract infections in patients with diabetes treated with dapagliflozin

(2013) Kristina M. Johnsson et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

(2013) Kristina M. Johnsson et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

(2013) Donald E. Kohan et al.   KIDNEY INTERNATIONAL

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus

(2013) Carl V. Asche et al.   PHARMACOECONOMICS

Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data

(2013) Eiji Kurosaki et al.   PHARMACOLOGY & THERAPEUTICS

Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes

(2013) André J. Scheen   POSTGRADUATE MEDICINE

Impact of Sodium Glucose Cotransporter 2 Inhibitors on Weight in Patients With Type 2 Diabetes Mellitus

(2013) Anthony H. Barnett   POSTGRADUATE MEDICINE

Effects of Dapagliflozin on Cardiovascular Risk Factors

(2013) Agata Ptaszynska et al.   POSTGRADUATE MEDICINE

Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials

(2013) Asres Berhan et al.   BMC Endocrine Disorders

SGLT inhibitors in management of diabetes

(2013) Abd A Tahrani et al.   Lancet Diabetes & Endocrinology

SGLT2 versus DPP4 inhibitors for type 2 diabetes

(2013) André J Scheen   Lancet Diabetes & Endocrinology

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

(2013) Tim Heise et al.   Diabetes Therapy

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

(2012) Sreeneeranj Kasichayanula et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

(2012) B Zambrowicz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Combination Treatment With Ipragliflozin and Metformin: A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Type 2 Diabetes Mellitus

(2012) Stephan A. Veltkamp et al.   CLINICAL THERAPEUTICS

Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study

(2012) L.E. Nicolle et al.   CURRENT MEDICAL RESEARCH AND OPINION

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor

(2012) Paul Nyirjesy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effects of SGLT2 inhibitors on cardiovascular outcomes

(2012) Celine Foote et al.   Diabetes & Vascular Disease Research

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

(2012) J. Rosenstock et al.   DIABETES CARE

No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects

(2012) R. A. Smulders et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study

(2012) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

(2012) Ö. Ljunggren et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range

(2012) C. J. Bailey et al.   DIABETES OBESITY & METABOLISM

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

(2012) D. Devineni et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

(2012) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Dapagliflozin

(2012) Greg L. Plosker   DRUGS

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

(2012) R. R. Henry et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

(2012) Vivian A. Fonseca et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials

(2011) Giovanni Musso et al.   ANNALS OF MEDICINE

Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney

(2011) Volker Vallon et al.   Annual Review of Physiology

Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study

(2011) Sreeneeranj Kasichayanula et al.   CLINICAL THERAPEUTICS

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

(2011) R. L. Dobbins et al.   DIABETES OBESITY & METABOLISM

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

(2011) S. Sha et al.   DIABETES OBESITY & METABOLISM

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

(2011) K. Strojek et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

(2011) Sherwyn L. Schwartz et al.   Diabetes Technology & Therapeutics

Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes

(2011) Muhammad A. Abdul-Ghani et al.   ENDOCRINE REVIEWS

Management of type 2 diabetes: new and future developments in treatment

(2011) Abd A Tahrani et al.   LANCET

Renal glucose reabsorption inhibitors to treat diabetes

(2011) Clifford J. Bailey   TRENDS IN PHARMACOLOGICAL SCIENCES

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Sodium-Glucose Co-Transport Inhibitors

(2010) Joshua J. Neumiller et al.   DRUGS

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE